Michael Makris on Immediate Suspension of Use of Plasma Derived FIX Concentrates in Punjab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”This is worrying.
The Tribune newspaper in India is reporting that authorities have asked for the immediate suspension of use (and quarantining) of six batches of plasma derived factor IX concentrate for use in haemophilia B.
The products are made by a company called ICHOR Biologics, a company I have not heard of before.
The article is missing two critical pieces of information:
a) What is the adverse event that led to the suspension of this product
b) How many patients are affected. Only the total number of patients in the region are given.
I really hope this is not new transmission of a viral infection in persons with haemophilia.
The story may be a local one in Punjab in India, but the international world of haemophilia will be following this story.”
Read The Tribune article here.
Stay updated on the emerging with Hemostasis Today.
-
Apr 9, 2026, 16:40We Are Incredibly Grateful to Our Volunteers – Hemophilia of Georgia
-
Apr 9, 2026, 15:10Christoffer Gebhardt: Can Anticoagulation Improve Outcomes in Melanoma Therapy?
-
Apr 9, 2026, 15:09National Institutes of Health Addresses VTE Research Funding Gap – JTH
-
Apr 9, 2026, 15:08Alice Assinger: Recruiting PhD Students for NET-IT Doctoral Program in Vienna
-
Apr 9, 2026, 15:07Hannah Cohen: A Novel Approach to Post-Stroke Gait Rehabilitation
-
Apr 9, 2026, 15:07Shehab Mohamed: A Single-Center Experience on Stroke Risk in Polycythemia Vera
-
Apr 9, 2026, 15:06Catch the Brand-New Recap of the Phase III OCEANIC-STROKE Trial – ISTH
-
Apr 9, 2026, 15:06Neeraj Jain: Building Capacity for Better Haemoglobinopathy Care in Maharashtra
-
Apr 9, 2026, 15:05Esther Nakkazi: Armenia Leads WHO Resolution to Advance Haemophilia Care Worldwide